ATE540053T1 - Fermentationsprozess zur produktion von diphtherie-toxin - Google Patents

Fermentationsprozess zur produktion von diphtherie-toxin

Info

Publication number
ATE540053T1
ATE540053T1 AT09176267T AT09176267T ATE540053T1 AT E540053 T1 ATE540053 T1 AT E540053T1 AT 09176267 T AT09176267 T AT 09176267T AT 09176267 T AT09176267 T AT 09176267T AT E540053 T1 ATE540053 T1 AT E540053T1
Authority
AT
Austria
Prior art keywords
fermentation process
diphtheria toxin
producing diphtheria
producing
culture
Prior art date
Application number
AT09176267T
Other languages
English (en)
Inventor
Phillippe Marc Helene Dehottay
Sandrine Dessoy
Olivier Marc Serge Ghislain Laloux
Marc Roger Fernand Orval
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Application granted granted Critical
Publication of ATE540053T1 publication Critical patent/ATE540053T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1077—Pentosyltransferases (2.4.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/77—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Corynebacterium; for Brevibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT09176267T 2005-03-23 2006-03-21 Fermentationsprozess zur produktion von diphtherie-toxin ATE540053T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0505996.9A GB0505996D0 (en) 2005-03-23 2005-03-23 Fermentation process

Publications (1)

Publication Number Publication Date
ATE540053T1 true ATE540053T1 (de) 2012-01-15

Family

ID=34531759

Family Applications (2)

Application Number Title Priority Date Filing Date
AT09176267T ATE540053T1 (de) 2005-03-23 2006-03-21 Fermentationsprozess zur produktion von diphtherie-toxin
AT06723804T ATE449788T1 (de) 2005-03-23 2006-03-21 Fermentationsverfahren zur herstellung von diphterietoxin

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT06723804T ATE449788T1 (de) 2005-03-23 2006-03-21 Fermentationsverfahren zur herstellung von diphterietoxin

Country Status (14)

Country Link
US (2) US20080193475A1 (de)
EP (2) EP2174950B1 (de)
JP (1) JP4917087B2 (de)
KR (1) KR101341121B1 (de)
CN (1) CN101180313B (de)
AT (2) ATE540053T1 (de)
AU (1) AU2006226542B2 (de)
BR (1) BRPI0609692C1 (de)
CA (1) CA2602143C (de)
DE (1) DE602006010676D1 (de)
ES (2) ES2335133T3 (de)
GB (1) GB0505996D0 (de)
RU (1) RU2394914C2 (de)
WO (1) WO2006100108A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ591103A (en) * 2008-07-21 2013-02-22 Brigham & Womens Hospital Methods and compositions relating to synthetic beta-1,6 glucosamine oligosaccharides
IT1398927B1 (it) 2009-06-25 2013-03-28 Consorzio Interuniversitario Per Lo Sviluppo Dei Sistemi A Grande Interfase Csgi Espressione batterica di un gene artificiale per la produzione di crm197 e derivati.
GB0917647D0 (en) 2009-10-08 2009-11-25 Glaxosmithkline Biolog Sa Expression system
CN104379170B (zh) 2012-06-20 2017-05-03 国立大学法人东京大学 粘膜免疫刺激剂及hpv感染症治疗用经口药物组合物
CN103627758B (zh) * 2012-08-28 2018-04-27 天士力医药集团股份有限公司 一种crm197蛋白的生产方法
US20140193451A1 (en) * 2012-10-17 2014-07-10 Glaxosmithkline Biologicals Sa Immunogenic composition
AR095425A1 (es) 2013-03-15 2015-10-14 Glaxosmithkline Biologicals Sa Vacuna, uso y procedimiento para prevenir una infección por picornavirus
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
MX2019007910A (es) 2016-12-30 2019-12-05 Sutrovax Inc Conjugados de polipeptido-antigeno con aminoacidos no naturales.
WO2018156465A1 (en) * 2017-02-24 2018-08-30 Merck Sharp & Dohme Corp. Polysaccharide-protein conjugates utilizing diphtheria toxin fragment b as a carrier
EA201992527A1 (ru) * 2017-04-22 2020-02-28 Байолоджикал И Лимитед Улучшенный способ крупномасштабного производства crm
US12397014B2 (en) 2019-02-05 2025-08-26 The Brigham And Women's Hospital, Inc. Polysaccharide compositions for use in treating filariasis
EP3699263A1 (de) 2019-02-22 2020-08-26 GlaxoSmithKline Biologicals S.A. Gärungsprozess
CN110452838B (zh) * 2019-07-18 2020-12-29 艾美卫信生物药业（浙江）有限公司 一种crm197菌种培养基、配制方法及发酵培养方法
WO2021176409A1 (en) 2020-03-05 2021-09-10 Sanofi Healthcare India Private Limited Preservative combination for vaccine composition
CN115058474B (zh) * 2022-05-23 2025-02-14 艾美坚持生物制药有限公司 一种提高crm197蛋白产量的发酵培养方法
CN114806973B (zh) * 2022-06-08 2024-02-23 艾美坚持生物制药有限公司 一种提高crm197蛋白产量的生长因子及其制备方法和应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
EP0027888B1 (de) 1979-09-21 1986-04-16 Hitachi, Ltd. Halbleiterschalter
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
CH660375A5 (it) 1983-02-08 1987-04-15 Sclavo Spa Procedimento per la produzione di proteine correlate alla tossina difterica.
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
US4950740A (en) 1987-03-17 1990-08-21 Cetus Corporation Recombinant diphtheria vaccines
MC2178A1 (fr) 1988-12-16 1992-05-22 Nederlanden Staat Mutants de la pneumolysine et vaccins a base de pneumocoque prepares a partir de ces mutants
WO1991013090A1 (en) 1990-03-02 1991-09-05 Diane Williams Improved chimeric toxins
DE69133276T2 (de) 1990-07-16 2003-11-27 University Of North Carolina At Chapel Hill, Chapel Hill Mit der familie der hämolysin-toxine verwandte antigene eisen-ubnterdrückende proteine des n. meningitis
US5912336A (en) 1990-08-23 1999-06-15 University Of North Carolina At Chapel Hill Isolated nucleic acid molecules encoding transferrin binding proteins from Neisseria gonorrhoeae and Neisseria meningitidis
JP3532563B2 (ja) 1990-08-23 2004-05-31 ザ ユニバーシティー オブ ノースカロライナ アット チャペル ヒル Ｎｅｉｓｓｅｒｉａ ｇｏｎｏｒｒｈｏｅａｅおよびＮｅｉｓｓｅｒｉａ ｍｅｎｉｎｇｉｔｉｄｉｓ由来トランスフェリン結合蛋白質
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
US6592876B1 (en) 1993-04-20 2003-07-15 Uab Research Foundation Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products
US5476929A (en) 1991-02-15 1995-12-19 Uab Research Foundation Structural gene of pneumococcal protein
FR2682041B1 (fr) 1991-10-03 1994-01-14 Pasteur Merieux Serums Vaccins Vaccin contre les infections a neisseria meningitidis.
AU685047B2 (en) 1992-02-11 1998-01-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine Dual carrier immunogenic construct
ATE178907T1 (de) 1992-05-06 1999-04-15 Harvard College Rezeptorbindende region des diphtherietoxius
DE69319728T2 (de) 1992-05-23 1999-02-04 Smithkline Beecham Biologicals S.A., Rixensart Kombinierte Impfstoffe, die Hepatitis B oberfläche Antigen und andere Antigenen enthalten
JP3428646B2 (ja) 1992-06-18 2003-07-22 プレジデント アンド フェローズ オブ ハーバードカレッジ ジフテリア毒素ワクチン
FR2692592B1 (fr) 1992-06-19 1995-03-31 Pasteur Merieux Serums Vacc Fragments d'ADN codant pour les sous-unités du récepteur de la transferrine de Neisseria meningitidis et procédés les exprimant.
ES2126616T3 (es) * 1992-10-27 1999-04-01 American Cyanamid Co Vacuna pediatrica combinada, con una inmunogenecidad aumentada de cada componente de la vacuna.
ES2231770T3 (es) 1993-03-05 2005-05-16 Wyeth Holdings Corporation Nuevos plasmidos para la produccion de proteina crm y toxina difterica.
ES2185658T3 (es) 1993-05-18 2003-05-01 Univ Ohio State Res Found Vacuna para la otitis media.
US6455673B1 (en) 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
US5917017A (en) * 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
US5565204A (en) 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
US6265567B1 (en) 1995-04-07 2001-07-24 University Of North Carolina At Chapel Hill Isolated FrpB nucleic acid molecule
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
AU700080B2 (en) 1995-06-07 1998-12-17 Biochem Vaccines Inc. Streptococcal heat shock proteins members of the HSP70 family
IL122588A (en) 1995-06-23 2001-12-23 Smithkline Beecham Biolog A combination vaccine containing a polysaccharide conjugated antigen attached to a phosphate aluminum and one or more additional antibodies
EP0912608B1 (de) 1996-05-01 2006-04-19 The Rockefeller University Cholin-bindendes Protein, welches als gegen Pneumokokken gerichtetes Vakzin verwendet wird
FR2751000B1 (fr) 1996-07-12 1998-10-30 Inst Nat Sante Rech Med Adn specifiques des bacteries de l'espece neisseria meningitidis, leurs procedes d'obtention et leurs applications biologiques
US5882871A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation Saliva binding protein
US5882896A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation M protein
CA2271720A1 (en) 1996-10-31 1998-05-07 Human Genome Sciences, Inc. Streptococcus pneumoniae polynucleotides and sequences
AU740956B2 (en) 1997-07-21 2001-11-15 Baxter Healthcare Sa Modified immunogenic pneumolysin compositions as vaccines
GB9717953D0 (en) 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
GB9726398D0 (en) 1997-12-12 1998-02-11 Isis Innovation Polypeptide and coding sequences
EP1067962B1 (de) 1998-04-07 2010-03-24 MedImmune, LLC Choline-bindende proteine derivate aus pneumokoken als impfstoff
EP2261347A3 (de) 1998-05-01 2012-01-11 Novartis Vaccines and Diagnostics, Inc. Antigene und Zusammensetzungen gegen Neisseria meningitidis
CA2347849C (en) 1998-10-22 2013-06-25 The University Of Montana Omp85 proteins of neisseria gonorrhoeae and neisseria meningitidis, compositions containing same and methods of use thereof
GB9904582D0 (en) 1999-02-26 1999-04-21 Nycomed Imaging As Process
KR100401423B1 (ko) 2001-01-10 2003-10-17 주식회사 엘지생명과학 혼합 백신의 제조 방법
WO2006042542A2 (en) * 2004-10-19 2006-04-27 Statens Serum Institut Production of tetanus, diphtheria, and pertussis toxins and toxoids using fermentation media containing no components of animal or soy origin
US9473463B2 (en) 2014-07-29 2016-10-18 Combined Conditional Access Development & Support, LLC Control word and associated entitlement control message caching and reuse

Also Published As

Publication number Publication date
CA2602143C (en) 2016-08-09
KR101341121B1 (ko) 2013-12-12
RU2007135122A (ru) 2009-04-27
ATE449788T1 (de) 2009-12-15
EP1861420A1 (de) 2007-12-05
BRPI0609692B8 (pt) 2020-01-21
US20140242635A1 (en) 2014-08-28
CA2602143A1 (en) 2006-09-28
EP2174950A1 (de) 2010-04-14
JP2008533980A (ja) 2008-08-28
BRPI0609692B1 (pt) 2019-02-12
JP4917087B2 (ja) 2012-04-18
ES2335133T3 (es) 2010-03-22
DE602006010676D1 (de) 2010-01-07
EP2174950B1 (de) 2012-01-04
WO2006100108A1 (en) 2006-09-28
GB0505996D0 (en) 2005-04-27
CN101180313A (zh) 2008-05-14
AU2006226542B2 (en) 2012-02-09
BRPI0609692C1 (pt) 2021-05-25
ES2378193T3 (es) 2012-04-09
EP1861420B1 (de) 2009-11-25
AU2006226542A1 (en) 2006-09-28
US20080193475A1 (en) 2008-08-14
CN101180313B (zh) 2012-10-03
KR20070116132A (ko) 2007-12-06
BRPI0609692A2 (pt) 2010-04-20
RU2394914C2 (ru) 2010-07-20

Similar Documents

Publication Publication Date Title
ATE449788T1 (de) Fermentationsverfahren zur herstellung von diphterietoxin
ATE542886T1 (de) Verfahren zur herstellung von l-arginin mit corynebacterium glutamicum
WO2009112472A3 (en) Selection of organisms capable of fermenting mixed substrates
ATE374531T1 (de) Verstaerkte produktion von lipiden enthaltend mehrfachungesaettigte fettsaeuren durch hochdichte kulturen von eukariotischen mikroben in gaervorrichtungen
ATE439427T1 (de) Neue kaumagenbakterienvarianten sowie verfahren zur herstellung von bernsteinsäure unter verwendung davon
Michielsen et al. Spatially structured microbial consortia and their role in food fermentations
ATE443757T1 (de) L-aminosäure produzierender mikroorganismus und verfahren zur l-aminosäureproduktion
DE602004014158D1 (de) Verfahren zur herstellung von l-lysin oder l-threonin unter verwendung von escherichia-bakterien mit abgeschwächter malatenzymaktivität
EP2848680A3 (de) Hefestämme und Verfahren zur Verwendung davon
IL160445A0 (en) A unit and a process for carrying out high cell density fermentation
DE60226243D1 (de) Peptidsynthasegen, peptidsynthase und verfahren zur herstellung eines dipeptids
ATE554159T1 (de) Zur produktion von l-aminosäure fähiger mikroorganismus und verfahren zur produktion von l-aminosäure
TW200420509A (en) Novel biological flocculants and production methods
WO2008102572A1 (ja) Ｌ－アミノ酸または核酸の製造方法
ATE551418T1 (de) Verfahren und vorrichtung zur anaeroben fermentation von organischem material
DE60206204D1 (de) Verfahren zur Herstellung von L-Glutaminsäure
ATE552345T1 (de) Verfahren zur herstellung von fermentationsprodukten
DK1776451T3 (da) Fremgangsmåde til fremstilling af L-aminosyrer under anvendelse af stammer fra familien enterobacteriaceae
DE60207914D1 (de) Verfahren zur Herstellung von L-Glutaminsäure
ATE386134T1 (de) Verfahren zur herstellung von glutathion
DE60006552D1 (de) Verfahren zur herstellung von exopolysaccharide
WO2004099426A8 (ja) L-グルタミン酸の製造法
ATE542887T1 (de) Neuartiger milchsäurebakterienstrang, fermentiertes nahrungsmittel/getränk und verfahren zur herstellung eines fermentierten nahrungsmittels/getränks
KR20140092533A (ko) 관상어 사육환경에 특이적인 미생물종으로 구성된 수질개선제
JP6925169B2 (ja) 有機酸産出促進剤、有機酸の製造方法及び培養方法